Delving into the Latest Updates on Anthralin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Anthralin (USP), Dithranol, Dithranol (INN)

+ [10]

Target-

Action-

Mechanism-

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal Diseases

Active Indication

Psoriasis

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC14H10O3

InChIKeyNUZWLKWWNNJHPT-UHFFFAOYSA-N

CAS Registry1143-38-0

Psoriasis is a common immune mediated inflammatory skin disease characterized by red heavily scaled plaques. Anthralin (1,8-dihydroxy-9-anthrone) which was introduced over 80 years ago has shown excellent efficacy in the management of psoriasis.Although anthralin is remarkably effective in the management of psoriasis, its side effects are equally disturbing. Its use is messy as it stains the skin, clothing, and any furniture that it may come in contact with. Further, anthralin has irritating, burning, brown discoloration and necrotizing effect on the normal and the diseased skin. This troublesome profile has discouraged wide-spread use of the drug.
Ethosomes are attractive vesicular carriers mainly composed of phospholipids, ethanol and water. The intriguing features of ethosomes are due to their high ethanol content which facilitate their penetration through stratum corneum and target deep skin layers. This is advantageous over conventional liposomes which have limited penetration through the skin and remain confined in the upper layer of the stratum corneum. Compared to liposomes, ethosomes had greater retention of methotrexate into the skin for a longer period of time, suggesting better therapeutic outcome.

Start Date30 Nov 2017

Sponsor / Collaborator

Assiut University

100 Clinical Results associated with Anthralin

Login to view more data

100 Translational Medicine associated with Anthralin

Login to view more data

100 Patents (Medical) associated with Anthralin

Login to view more data

1,294

Literatures (Medical) associated with Anthralin

01 Oct 2025·JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

Psoriasis treated with dithranol: a pilot study on in vivo reflectance confocal microscopy

Article

Author: Enk, Alexander ; Toberer, Ferdinand ; Schirra‐Hoffmann, Astrid ; Winkler, Julia K. ; Haenssle, Holger A. ; Vogelgsang, Lena

Summary:

Background:

There are only limited histomorphological data on the response of psoriatic skin lesions to topical dithranol. In vivo reflectance confocal microscopy (RCM) in psoriatic skin is highly correlated with histopathological findings and allows non‐invasive monitoring of treatment effects on a cellular level.

Patients and Methods:

Prospective, single‐center pilot study at a university‐based clinic of dermatology between January 1 st and August 30 th , 2016. Psoriatic lesions of 20 patients receiving dithranol treatment were assessed by RCM at baseline, day 4 and 8 of treatment.

Results:

RCM measurements of psoriatic lesions receiving dithranol treatment revealed epidermal histomorphological changes with a strong median reduction of baseline hyperkeratosis by 45.0% ( p < 0.001), acanthosis by 38.2% ( p < 0.001), and epidermal thickness by 66.5% (p < 0.001) from baseline until day 8. Moreover, semiquantitative measurements of parakeratosis also showed a significant reduction until day 8 ( p < 0.001). Correspondingly, RCM revealed dermal histomorphological changes with a decrease in diameter of dermal papillae by 32.1% ( p < 0.001), decrease in diameter of papillary vessels by 16.9% ( p = 0.002) and a strong semiquantitative reduction of the inflammatory infiltrate ( p < 0.001).

Conclusions:

Results from our pilot study indicate that topical dithranol treatment of psoriatic lesions may induce a rapid and marked reduction of pathologic epidermal and dermal RCM features.

01 Aug 2025·JOURNAL OF DERMATOLOGICAL SCIENCE

Mast cells express IL17A, IL17F and RORC in lesional psoriatic skin, are activated before therapy and persist in high numbers in a resting state with IL-17A positivity after treatment

Article

Author: Salmhofer, Wolfgang ; Weger, Wolfgang ; Babina, Magda ; Benezeder, Theresa ; Bordag, Natalie ; El-Heliebi, Amin ; Woltsche, Johannes ; Gruber-Wackernagel, Alexandra ; Zhan, Qian ; Clark, Rachael ; Perchthaler, Isabella ; Wolf, Peter ; Teufelberger, Andrea ; Painsi, Clemens

BACKGROUND:

The proinflammatory cytokine IL-17 is known to play an important role in psoriasis pathogenesis, but little is known about its regulation in psoriasis or after treatment.

OBJECTIVE:

Aiming to investigate the role of IL-17 regulation in the resolution of psoriasis, we analyzed biopsy samples from patients with plaque psoriasis, including non-lesional and lesional skin at baseline and after anti-IL-17 and -IL-23 antibody, topical dithranol or UVB treatment as well as skin from healthy donors.

METHODS:

Skin biopsy samples were analyzed using immunostaining, RNA sequencing and in situ mRNA detection. In addition, we investigated IL-17 concentration of primary human skin mast cell supernatants after stimulation with the pro-inflammatory cytokines TNFα, IL-22, IL-23 and IFNγ.

RESULTS:

A high number of IL-17A+ mast cells persisted in resolved lesions after treatment and correlated inversely with the time span in remission. IL-17A+ mast cells were found in T cell-rich areas and near resident memory T cells in active and resolved lesions. CIBERSORTx deconvolution of RNA-seq data of active and dithranol-treated psoriasis lesions showed that activated mast cells were increased in psoriatic skin but returned to normal levels after treatment. Primary skin mast cells responded with an increased release of IL-17A after stimulation with the pro-inflammatory cytokines and in situ mRNA detection revealed positive signals for IL17A, IL17F and RORC in mast cells.

CONCLUSION:

Thus, together with T cells, mast cells seem to be important players of the IL-23/IL17 axis underlying psoriasis pathogenesis and relevant for early disease recurrence.

01 Jul 2025·The Journal of clinical and aesthetic dermatology

Treatment of Recalcitrant Scalp Psoriasis with Topical Roflumilast Cream 0.3%: A Case Report.

Article

Author: Domingues, Erik

Scalp psoriasis is a chronic immune skin disease affecting up to 80 percent of patients with psoriasis. Treatments include topical steroids, keratolytics, tar, anthralin, vitamin D analogs, and retinoids. However, treatment can be difficult due to the presence of hair. Roflumilast 0.3% cream was approved in 2022 for the treatment of chronic plaque psoriasis, including intertriginous areas. Here, we present the case of a 28-year-old female patient with scalp psoriasis, who had previously trialed both topical and systemic treatments for her disease without success. Use of once daily roflumilast 0.3% cream resulted in rapid scalp psoriasis clearance, with results seen as early as Day 3 and complete clearance by Day 5 of treatment without adverse events or tolerability concerns.

100 Deals associated with Anthralin

Login to view more data